PPARA and obesity disorder: Although the blood glucose lowering effect of MD001 was lower than that of rosiglitazone, the MD001-mediated increase in fatty acid oxidation via PPARα activation suggests that MD001 may have favourable effects on hyperlipidaemia and obesity without inducing body weight gain, at least in part.